Despite Safety Concerns, FDA Approves Moderna’s mRNA Flu Shot
On Aug. 5, 2026, the U.S. Food and Drug Administration (FDA) approved Moderna’s seasonal flu shot, mFLUSIVA (mRNA-1010), making it the first messenger RNA platform for seasonal influenza in the United States. The decision permits health care providers to use mRNA technology for annual influenza vaccination in eligible age groups.1 FDA regulators approved mFLUSIVA to […]
Vaccines Can Cause Injury and Death. Scientific Fact, Not Disinformation.
In a prepared statement released on Aug. 12, 2025, the American Federation of Government Employees (AFGE), Local 2883, urged the U.S. Centers for Disease Control and Prevention (CDC) and the leadership of the Department of Health and Human Services (DHHS) to provide a “clear and unequivocal stance in condemning vaccine disinformation.”1 2 3 The union, […]
Pre-filled Syringe Version of GSK’s Shingles Vaccine Approved by FDA
On July 17, 2025, officials at the U.S. Food and Drug Administration (FDA) granted a license to GSK plc (formerly GlaxoSmithKline) to distribute a pre-filled syringe version of Shingrix (Zoster Vaccine Recombinant Adjuvanted) vaccine to control outbreaks of shingles (herpes zoster) in adults. The pre-filled syringe version of Shingrix was approved for use by adults […]
Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia
In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]
Moderna Continues mRNA Norovirus “Vaccine” Trials Following Guillain-Barré Case
A first-ever norovirus “vaccine”—another experimental biological product produced by Moderna, Inc., using novel mRNA technology—may be on the horizon even though last month the U.S. Food and Drug Administration (FDA) paused Moderna’s late-stage clinical trial following a report of Guillain-Barré syndrome (GBS), a rare neurological side effect that has also surfaced in its RSV vaccine […]
FDA Requires RSV Vaccine Labels to Include Guillain-Barré Syndrome Risk
On Jan. 7, 2025, the U.S. Food and Drug Administration (FDA) mandated and approved changes to the safety labeling for the Prescribing Information of two Respiratory Syncytial Virus (RSV) vaccines: Abrysvo (manufactured by Pfizer)1 and Arexvy (manufactured by GlaxoSmithKline Biologicals).2 This label change update is being required to inform both the public and health care […]